Related Experiment Video
Updated: Mar 14, 2026
A High-throughput Shigella-specific Bactericidal Assay
Published on: February 27, 2019
Shigella Vaccine Development: Finding the Path of Least Resistance
Wilbur H Chen1,2, Karen L Kotloff3,4,2
1Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA wchen@medicine.umaryland.edu.
Abstract:
Shigella spp. represent the second most common etiologic pathogen causing childhood diarrhea in developing countries. There are no licensed Shigella vaccines, and progress for such vaccines has been limited. In this issue of Clinical and Vaccine Immunology, Riddle and colleagues (M. S. Riddle, R. W. Kaminski, C. Di Paolo, C. K. Porter, R. L. Gutierrez, et al., Clin Vaccine Immunol 23:908-917, 2016, http://dx.doi.org/10.1128/CVI.00224-16) report results from a phase I study of a parenterally administered monovalent O-polysaccharide "bioconjugate" directed against Shigella flexneri 2a. Ultimately, the goal is to develop a broad-spectrum Shigella vaccine to address this public health concern. A parenteral Shigella vaccine capable of eliciting protection in children of developing countries would be an important tool to reach this goal.
